More Bad News For Pozen: Another Delay To Market For Yosprala
This article was originally published in The Pink Sheet Daily
Executive Summary
The company received a second “complete response” letter from FDA for Yosprala, its fixed-dose combination of aspirin and omeprazole, due to issues with the undisclosed third-party supplier.